

NOTE: This order is nonprecedential.

**United States Court of Appeals
for the Federal Circuit**

In Re ENTRESTO (SACUBITRIL/VALSARTAN)

NOVARTIS PHARMACEUTICALS CORPORATION,
Plaintiff-Appellant

v.

**MSN PHARMACEUTICALS, INC., MSN
LABORATORIES PRIVATE LTD., MSN LIFE
SCIENCES PRIVATE LTD.,**
Defendants-Appellees

2025-1927, 2025-1928

Appeals from the United States District Court for the
District of Delaware in Nos. 1:20-md-02930-RGA and 1:22-
cv-01395-RGA, Judge Richard G. Andrews.

ON MOTION

PER CURIAM.

O R D E R

Pursuant to Rule 8 of the Federal Rules of Appellate
Procedure, Novartis Pharmaceuticals Corporation

(“Novartis”) submits a motion to enjoin, pending appeal, MSN Pharmaceuticals, Inc., MSN Laboratories Private Ltd., and MSN Life Sciences Private Ltd. (collectively, “MSN”) from commercial marketing and sale of their generic version of Novartis’s Entresto® product. Novartis also requests a temporary injunction pending consideration of the Rule 8 motion. MSN files an opposition to that request.

Upon consideration thereof,

IT IS ORDERED THAT:

(1) MSN is directed to respond to Novartis’s motion no later than 12:00 p.m., July 18, 2025. Any reply is due no later than 5 p.m., July 21, 2025.

(2) MSN is temporarily enjoined from commercial marketing and sale of its generic version of Entresto® pending this court’s consideration of the Rule 8 motion.

(3) Novartis is directed to file a bond in the district court in an amount, and subject to terms and conditions, deemed appropriate by the district court.

(4) Appeal No. 2025-1927 and Appeal No. 2025-1928 are consolidated, and the official caption is reflected in this order. The parties should file one set of briefs for both appeals.

FOR THE COURT



Jarrett B. Perlow
Clerk of Court

July 15, 2025
Date